Concepedia

David Kallend

DK

Statistics

Publications

55

Citations

10.8K

H-Index

39

Active since

2004

Affiliations

Roche (Switzerland)(Current)

University of Toronto

Doctors Company (United States)

St. Michael's Hospital

Amsterdam UMC Location University of Amsterdam

David Kallend is an author at Roche (Switzerland) specializing in clinical pharmacology, pharmacology, and lipid-lowering therapy.

ORCID

Publications per year

2004–2025

55

Publications

55

Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome

Gregory G. Schwartz, Anders Olsson, Markus Abt et al. · New England Journal of Medicine · 2012 · 2K citations · Full text

, , +17

Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol

Kausik K. Ray, R. Scott Wright, David Kallend et al. · New England Journal of Medicine · 2020 · 1.6K citations · Full text

, , +17

Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol

Kausik K. Ray, Ulf Landmesser, Lawrence A. Leiter et al. · New England Journal of Medicine · 2017 · 977 citations · Full text

, , +17

Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia

Frederick J. Raal, David Kallend, Kausik K. Ray et al. · New England Journal of Medicine · 2020 · 801 citations · Full text

, , +13

A Highly Durable RNAi Therapeutic Inhibitor of PCSK9

Kevin Fitzgerald, Suellen White, Anna Borodovsky et al. · New England Journal of Medicine · 2016 · 760 citations · Full text

, , +17

1–5 of 55